Hirudoid

Quick links to important sections

Hirudoid

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hirudoid

Property Description
Active ingredient Chondroitin Polysulfate (Mucopolysaccharide Polysulfate)
Form Topical Cream, Topical Gel, Ointment
Pharmacological class Heparinoid, Topical Anti-inflammatory Agent
General Purpose Supports resolution of swelling and localized tissue discomfort
Origin Synthetic derivative

What Type of Medicine is Hirudoid and What is its Composition?

Hirudoid is a topical medicinal product intended for external use, classified primarily as a Heparinoid and an Anti-inflammatory Agent. The active ingredient is Chondroitin Polysulfate, also known by its chemical synonym, Mucopolysaccharide Polysulfate (MPS). This compound is a synthetic derivative of Heparin, classifying it within the high-level group of Glycosaminoglycan Derivatives. The preparation is available in specialized Dosage forms, specifically as a Topical Cream or a Topical Gel, which are often favored for their aesthetic qualities and ease of application. The cream utilizes an aqueous-emulsion base, while the gel is hydro-alcoholic. Topical MPS is associated with the improvement of the skin's barrier function and hydration.


What is the General Purpose of Hirudoid?

The general purpose of Hirudoid is to support the resolution of localized tissue disturbances by leveraging its inherent physiological actions. The Mucopolysaccharide Polysulfate provides a dual-action benefit: it exhibits an Anti-inflammatory effect that helps lessen localized swelling and irritation, and it possesses Antithrombotic properties for supporting microcirculation. By concurrently aiding local blood flow and assisting in the clearance of accumulated fluid, the medication supports the body’s recovery from tissue stress. Topical Heparinoids, including MPS, have effects on reducing edema and inflammation when applied locally. This informs the agent's general role in easing localized discomfort associated with swelling, often utilized in scenarios such as recovery from blunt injuries and issues affecting the superficial veins.

What side effects are possible with Hirudoid?

This section outlines the officially documented adverse reactions and safety restrictions for Hirudoid (Mucopolysaccharide Polysulphate) as reported in government regulatory documents.

Adverse Reactions by Frequency

The most common adverse effects are localized, affecting the application site. Reactions are generally mild and temporary.

Classification Type of Adverse Reaction System Organ Class
Uncommon (ge 1/1,000 to < 1/100) Local skin reactions (e.g., redness/erythema, local pain) Skin and Subcutaneous Tissue Disorders
Rare (ge 1/10,000 to < 1/1,000) Hypersensitivity reactions (e.g., burning sensation, pruritus, blistering, rash) Immune System Disorders
Frequency Not Known Contact Dermatitis Skin and Subcutaneous Tissue Disorders

Safety Restrictions and Limitations

The official labeling mandates strict limitations on where the product can be applied to manage the risk of irritation and absorption.

  • Contraindications: The product is contraindicated in individuals with known hypersensitivity (allergy) to Mucopolysaccharide Polysulphate or any of the inactive ingredients (excipients).
  • Application Restrictions: It must not be used on broken skin, open wounds, mucous membranes (such as the mouth or nose), or the eyes.
  • Discontinuation Advice: In the event of a rash or allergic reaction, treatment must be discontinued immediately.
  • Excipient Warnings: Regulatory documents note that certain excipients, such as Propyl and Methyl parahydroxybenzoate, may cause allergic reactions (potentially delayed). Cetostearyl alcohol may cause local skin reactions like contact dermatitis.

Population and Exposure Notes

Side effects like hypersensitivity reactions are generally noted to subside rapidly once the use of the preparation is stopped. Safety data is generally limited for the paediatric population below certain age limits (e.g., 5 or 12 years old, depending on the specific label), and caution is advised.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Hirudoid (Chondroitin Polysulfate) addresses overdose primarily in the context of the product’s formulation and route of administration.

Overdose associated with topical application is unlikely to cause systemic effects, as indicated by official labeling. The main scenario addressed is the accidental ingestion (swallowing) of the cream or gel.


Official Regulatory Stance on Overdose

Feature Official Regulatory Statement
Documented Manifestations None explicitly detailed; the regulatory basis notes an absence of reported cases.
Serious Outcomes Accidental ingestion is characterized as unlikely to be serious.
Supportive Measures General supportive measures may be appropriate.

Required Emergency Action

While ingestion is assessed as unlikely to be serious, immediate medical attention is required for any accidental swallowing of the product. The user must contact a doctor or hospital casualty department immediately for assessment and necessary monitoring. This action is mandated because no specific advice is available regarding symptoms in the regulatory documentation for the single-ingredient formulation.

Therapeutic Uses of Hirudoid

What Hirudoid Treats: Main Uses and Benefits

The primary therapeutic use of this medication is applied across domains involving localized tissue disturbance. It is commonly used when short-term symptomatic assistance is needed to address pronounced symptoms of discomfort and swelling.

The medication helps address symptom clusters that may become intense or disruptive, including localized tenderness, redness, and a feeling of heaviness in the limbs. It is considered relevant for easing symptoms related to superficial thrombophlebitis and localized phlebitis, is relevant for easing symptoms related to subcutaneous blood collections (haematomas), and assists with addressing the physical symptoms of bruising and localized swelling following blunt injuries.

“This application provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

Quick Fact: Symptomatic Contexts

For conditions like certain hypertrophic scars and keloids, it is used to ease challenging symptoms related to tissue hardness and surface irregularity. It assists with maintaining functional stability by managing the localized physical symptoms that may interfere with daily functioning.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Hirudoid — official regulatory information

Hirudoid (containing the active substance heparinoid, or Mucopolysaccharide Polysulphate) is a topical medication with specific restrictions defining who can and cannot use it, based on official regulatory labeling.


Populations that Must Not Use Hirudoid (Contraindications)

Classification Restricted Population/Condition
Hypersensitivity Individuals with a known allergy or sensitivity to heparinoid (Mucopolysaccharide Polysulphate) or any of the specific excipients/ingredients in the product formulation (e.g., parabens, lanolin, cetostearyl alcohol).
Application Site Broken skin (including open or infected wounds), large areas of skin, or sensitive areas such as the eyes, mouth, ano-genital regions, or mucous membranes.
Age Restriction Children under the age of 5 years old are formally contraindicated.

Eligible Populations and Restrictions

  • Allowed Use: Hirudoid is indicated for use in adults and children over 5 years of age for topical application.
  • Pregnancy/Lactation: Regulatory information states there is no evidence to suggest that the preparation should not be used during pregnancy and lactation, indicating use is possible.
  • General Restriction: The product is for external use only and must not be swallowed. The stated dose should not be exceeded.

Regulatory Summary: Official documents establish absolute prohibitions (contraindications) based on hypersensitivity, age (under 5 years), and application site integrity. The allowed use is limited to adults and children over 5 years old for external application on intact skin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents from agencies such as the EMA and MHRA generally indicate that for Hirudoid (mucopolysaccharide polysulfate) in its topical cream or gel formulation, no systemic drug interactions are known or documented.

This conclusion is based on the pharmacokinetic profile of the product. Following cutaneous application, the amount of the active ingredient that reaches the systemic circulation is minimal, resulting in plasma concentrations that are below the threshold of physiological relevance for causing significant coagulation effects or systemic drug interactions.

Official Interaction Statements

Interaction Type Regulatory Status (Official Documentation)
Systemic Drug-Drug Interactions None Known / None Documented
Contraindicated Combinations None listed
Metabolic/CYP Interactions None documented due to minimal systemic absorption
Food, Alcohol, or Herbal Interactions None known

Interaction-Related Constraints

No specific medicinal products, food items, or supplements are explicitly listed in official labeling as being contraindicated or requiring dose separation when using topical Hirudoid. The regulatory interaction profile is defined by the absence of systemic risk, meaning there is no documented concern for effects on the metabolism or effectiveness of oral or injected medications.

Mechanism of Action

How Hirudoid Works

The mechanism of action for Mucopolysaccharide Polysulfate (MPS) is a localized, dual-action process that targets the microenvironment of the applied tissue.

MPS acts as an inhibitor against specific proteolytic enzymes, such as Hyaluronidase and Elastase. By reducing the degradation rate of Extracellular Matrix (ECM) components, this mechanism maintains the structural organization of connective tissue.

Simultaneously, MPS interacts with the capillary walls to reduce their permeability, thereby restricting the movement of fluid and plasma proteins into the tissue spaces. This action initiates a mechanistic cascade that promotes the gradient for interstitial fluid reabsorption, directly resulting in the physiological consequence of reduced interstitial fluid volume and localized tissue pressure.

As a Heparinoid, MPS exerts a minor, localized inhibitory effect on coagulation factors, which subtly influences the micro-coagulation cascade. This activity supports the clearance of small fibrin deposits and blood breakdown products, contributing to the maintenance of flow dynamics within the microcirculation. The mechanism operates within the layers of the epidermis, dermis, and subcutaneous tissue.

Dosage and Administration Information

How to Use Hirudoid

Hirudoid (Mucopolysaccharide Polysulfate) is administered via the topical route for external use, available in standardized 0.3% w/w cream and gel formulations. Its usage is defined by parameters regarding the quantity, frequency, and application technique associated with its use.


Official Administration Guidelines

Feature Guidelines
Route of Application Topical (intended for external use only).
Standard Dosing Apply a length of cream or gel measuring two to six inches (5–15 cm) to the affected area.
Dosing Frequency Application is made up to four times a day.
Age-Group Rules Approved for use in adults and children over 5 years of age; must not be used in children under 5.

Procedural Structure

The standard application involves the product being applied as a thin layer and gently massaged into the skin until fully absorbed. This massaging action is a key part of the application process. If the area requiring treatment is too tender to touch, the standard practice is to apply the product and massage it into the skin surrounding the site instead. The gel formulation is typically used in contexts where a cooling effect and rapid action are desired.

These guidelines define the approach for using the medication, with the duration of use typically continued until symptoms have subsided, within the established daily maximum frequency.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hirudoid

Research Evidence for Superficial Thrombophlebitis and Localized Phlebitis

Research was evaluated in conditions involving the superficial veins, such as superficial thrombophlebitis (STP) and general localized phlebitis. Research for this application includes Randomized Controlled Trials (RCTs) and analyses that combine data from multiple trials (systematic reviews). Research in this area has explored short-term symptom changes in observed populations.

Studies monitored outcomes related to physical discomfort, specifically pain intensity. Researchers also measured patterns related to the change in redness and tenderness over defined time intervals. Findings describe patterns observed in the studies regarding the evolution of symptoms in the observed populations during the acute phase of the condition.

Studies have provided limited information for complex disease progression in these populations. Evidence remains limited regarding the influence of local application on outcomes like deep vein thrombosis (DVT) progression. The studies focusing on episodes where symptoms become more noticeable are primarily short-term. For this reason, the sustained effects or long-term outcomes are not fully established in the available data.


Research Evidence for Bruising, Haematomas, and Localized Swelling

The topical agent was studied for its use following localized trauma, such as common bruising (haematomas) and swelling after a blunt injury. Research available includes placebo-controlled, double-blind clinical trials and investigations applied in contexts involving post-operative swelling and bruising. These studies research explored changes in outcomes describing episodic or acute changes and were applied in studies examining patient-reported experiences.

Research explored measurements of outcomes linked to inflammatory or irritative states, such as the physical size of the localized swelling (edema). Studies monitored the rate at which subcutaneous blood collections evolved in the observed populations. Data show patterns related to measured changes in swelling and the visual appearance of bruising, particularly over the short-term follow-up periods.


The Current Research Gaps and Uncertainties

When evaluating the overall research for this topical agent, certain constraints are noted. For acute conditions, the sample sizes were modest in many trials, and the evidence quality varies across studies, particularly when comparing the agent to a range of other treatments. The key uncertainty lies in that long-term effects are not fully established, as most trials prioritize acute, short-term relief.

Key Studies & References

  1. Clinical evaluation of topical heparinoid in the resolution of postoperative edema and ecchymosis following minor surgery

Frequently Asked Questions (FAQ)

Common questions about Hirudoid (FAQ)


Q: Is Hirudoid only available by prescription?

A: In many jurisdictions, Hirudoid is classified as a non-prescription medicine and can be purchased over-the-counter or from behind the pharmacy counter. However, the specific rules for dispensing may vary by country or region. It is important to check the local classification, as dispensing rules can vary by country.


Q: Can Hirudoid help with spider veins or varicose veins?

A: Official product information states that Hirudoid is indicated for the treatment of conditions associated with varicose veins, such as localized swelling (venous stasis edema) and inflammation of superficial veins. The product's indicated uses relate to managing symptoms associated with varicose veins, such as swelling, rather than cosmetic correction.


Q: Is Hirudoid effective for muscle pain or strains?

A: Information from some regulatory sources indicates that Hirudoid may be used to help relieve mild to moderate pain and swelling associated with minor conditions like muscle pain, stiffness, sprains, and strains. Its anti-inflammatory properties may help manage the pain and swelling associated with these localized injuries.


Q: How often should Hirudoid be applied per day?

A: According to official regulatory documents, the typical recommendation is to apply the cream or gel up to four times a day. Referencing the official product packaging is the best way to confirm the recommended application frequency.


Q: Is Hirudoid safe for use by older adults?

A: Yes, regulatory documentation confirms that Hirudoid is indicated for use in adults, and this includes older adults, as well as children over 5 years of age. Its use is limited to external application on intact skin.


Q: What happens if I forget to apply a dose of Hirudoid?

A: If a dose is missed, official patient guidance recommends that the application should be continued as usual with the next scheduled dose. Product guidance typically states not to use a double dose to compensate for a missed application.


Q: Can Hirudoid be used on the face for bruising?

A: Official warnings state that the product must not be used on sensitive areas like the eyes, mouth, or other mucous membranes. Due to restrictions around sensitive areas, cautious application is necessary to keep the product well away from the eyes and mucous membranes.


Q: What is the difference in concentration between Hirudoid cream and gel?

A: The active ingredient concentration, Mucopolysaccharide Polysulfate, is the same in both the cream and gel formulations, typically 0.3% w/w. The primary difference is in the base, with the gel formulation often noted in regulatory information for providing an additional cooling sensation upon application.


Q: What kind of research has been done on the efficacy of Hirudoid?

A: Research supporting the use of Hirudoid includes clinical studies, often randomized controlled trials, which evaluate its effects on localized symptoms. These studies focus on outcomes related to bruising (haematomas), superficial thrombophlebitis, and related swelling after trauma or surgery.


Q: Are there any alternative names for Hirudoid cream?

A: Hirudoid is a specific brand name. However, the active ingredient is known chemically by other names, including Mucopolysaccharide Polysulphate and Chondroitin Polysulfate. These names refer to the same compound that is responsible for its therapeutic effects.


Q: Can Hirudoid be used for contusions?

A: Yes, official therapeutic indications include the topical treatment of bruising (haematomas) and physical injuries. It is used to support the body’s resolution process for localized swelling and bruising following trauma, which includes contusions.


Q: Does Hirudoid absorb completely into the skin?

A: When applied topically, the product is intended to be gently massaged into the skin until fully absorbed. Pharmacokinetic studies show that the amount of the active ingredient that reaches the systemic bloodstream is minimal and is not considered physiologically significant.


Q: Is Hirudoid an anti-inflammatory drug?

A: Yes, Hirudoid is classified as a topical anti-inflammatory agent, in addition to being a heparinoid. Its mechanism of action includes influencing certain physiological processes that help reduce localized swelling and inflammation.


Q: Can I use Hirudoid if I have very sensitive skin?

A: The product is not recommended for use if there is a known allergy or hypersensitivity to any of its ingredients. Official warnings also note that certain non-active ingredients (excipients) can cause local skin reactions like contact dermatitis. If any persistent skin reactions occur, it is necessary to seek professional medical guidance.


Q: Is it safe to massage Hirudoid into the skin vigorously?

A: No, the official administration instructions specify that the cream or gel should be applied as a thin layer and 'gently massaged' into the skin until it is fully absorbed. Official instructions specify that the product should be 'gently massaged' into the skin; use of vigorous rubbing is outside the recommended technique.


Q: Can Hirudoid cause skin discoloration?

A: Official documentation lists common adverse reactions as localized skin changes, such as redness, irritation, and rash. While general skin discoloration is not a commonly listed side effect, if any persistent skin change occurs, it is appropriate to consult with a healthcare professional.


Q: Why do some people recommend chilling Hirudoid before use?

A: The gel formulation of Hirudoid is specifically mentioned in regulatory documents for use when a cooling effect is desired, such as for quick relief of painful or tender areas. The gel is intended for use when a cooling effect is desired, which aligns with common recommendations to chill the product before application.


Q: Is Hirudoid effective for treating chilblains?

A: Some external clinical sources and product information mention the use of Hirudoid to help manage the symptoms of chilblains. Its action as a heparinoid is known to influence microcirculation, which is a factor in managing symptoms related to chilblains.


Q: What are the signs that Hirudoid is not working for me?

A: If symptoms persist or worsen despite proper application, regulatory patient information suggests stopping use and consulting a healthcare professional. You should discontinue use if an allergic reaction occurs.


Q: Are there generic versions of Hirudoid available?

A: Hirudoid is a registered brand name. However, the active ingredient, Mucopolysaccharide Polysulphate, may be available in other products under different brand names or as a generic version, depending on the country.


Q: Is Hirudoid cream the same as heparin gel?

A: Hirudoid contains Mucopolysaccharide Polysulphate, which is chemically classified as a 'heparinoid,' meaning it is a synthetic derivative of heparin. While related, it is not the exact same chemical as sodium heparin, which is found in some other gels. Studies have compared the two agents for similar indications.


Q: What are the different types of Hirudoid available (e.g., cream, gel)?

A: Hirudoid is generally available as a topical cream and a topical gel. Both formulations contain the same concentration of the active ingredient, but the gel is often preferred for rapid action and its cooling effect, according to regulatory product information.


Q: Why is Hirudoid sometimes recommended for post-operative swelling?

A: The product is indicated for addressing swelling and bruising (haematomas), which are common issues after surgical procedures. Its anti-inflammatory and microcirculation support properties help to resolve the localized fluid accumulation and blood breakdown products.


Q: Is Hirudoid used for treating phlebitis?

A: Yes, the product is officially indicated for the soothing relief of symptoms associated with superficial thrombophlebitis and localized phlebitis (inflammation of the superficial veins).


Q: How does Hirudoid compare to arnica cream for bruising?

A: Limited clinical studies have been conducted comparing the effectiveness of the heparinoid in Hirudoid to the plant-derived compound in arnica cream for treating bruising and pain. Findings from some studies suggest that the effects of the two agents may be comparable in certain contexts.


Q: What is the typical duration of treatment with Hirudoid for a mild bruise?

A: Official guidance states that treatment should typically continue until the symptoms have completely subsided. For a mild bruise, some product information suggests that effectiveness and noticeable change may be observed within a short timeframe of approximately 3 to 5 days.


Q: Can I apply other lotions or creams over Hirudoid?

A: While there are no known systemic drug interactions documented for topical Hirudoid, it is generally advised to apply it as a thin layer and allow it to absorb fully. Applying multiple topical products simultaneously may potentially affect the absorption or efficacy of either product.


Q: How long can I use Hirudoid continuously?

A: The recommended duration of use is typically until the symptoms, such as the swelling or bruising, have completely resolved. Some regulatory advice indicates that there is no specific limit on how long one can continue to use the product, provided it is being used for its indicated purpose.

How should Hirudoid be stored and disposed of?

How to Store and Dispose of Hirudoid?

Official regulatory guidelines define specific conditions for storing and disposing of Hirudoid (Mucopolysaccharide Polysulfate) to maintain its stability and ensure safety.

Official Storage Requirements

Requirement Official Statement
Temperature Store below 25 C (Do not use after the expiry date)
Shelf-Life 5 years
Protection Keep out of the sight and reach of children

Official Disposal Rules

To protect the environment, the medicine should not be discarded via household waste or flushed down wastewater. Patients are instructed to return unused or expired product to a pharmacist for appropriate disposal. Use of the medicine is restricted after the expiration date printed on the tube and carton.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hirudoid found in:

A-Z Index: